Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2017 | Promising CLL & FL data from ICML 2017: BGB-3111 and obinituzumab

Susan O’Brien • 13 Jun 2017
ICML 2017
Chronic Lymphocytic Leukemia Antibodies BGB-3111 Ibrutinib Obinutuzumab Zanubrutinib

Susan O’Brien, MD from UC Irvine Health, Orange County, CA shares her stand-out abstract presented at the International Conference on Malignant Lymphoma (ICML) 2017, Lugano, Switzerland. Dr O’Brien describes the convincing and positive data,presented by Constantine Tam, which demonstrated the benefit of combining the second-generation BTK inhibitor, BGB-3111, and anti-CD20 agent, obinutuzumab, in the treatment of follicular lymphoma and chronic lymphocytic leukemia.

More from Susan O’Brien

2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien • 14 Jun 2019
2:19
CAR T-cell therapy updates in CLL
Susan O’Brien • 14 Jun 2019
2:00
CLL RESONATE-2: Five-year follow-up
Susan O’Brien • 13 Jun 2019
3:19
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
Susan O’Brien • 15 Jun 2019

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals